扶正养血膏干预化疗致骨髓抑制的临床疗效及安全性研究 点击下载
论文标题: 扶正养血膏干预化疗致骨髓抑制的临床疗效及安全性研究
英文标题:
中文摘要: 目的 观察扶正养血膏干预化疗致骨髓抑制的临床疗效及安全性。方法回顾性收集2018年1月-2020年12月于我院首次确诊为恶性肿瘤拟行“紫杉醇联合铂类”化疗方案的患者资料。患者共200例,根据有无使用扶正养血膏分为试验组和对照组,每组各100例。对照组常规化疗;试验组在首次化疗开始后联合口服扶正养血膏,直至该次化疗周期结束。比较2组患者首次出现骨髓抑制的时间、骨髓抑制发生率、补救用药情况和生活质量等指标。结果首次化疗后,对照组患者的白细胞计数、中性粒细胞计数、血小板和血红蛋白水平均显著低于首次化疗前(P<0.05);试验组患者的白细胞计数和中性粒细胞计数均显著低于首次化疗前(P<0.05),但显著高于对照组(P<0.05)。试验组患者骨髓抑制发生率(39.00%)显著低于对照组(63.00%)(P<0.05)。试验组首次出现骨髓抑制的时间(化疗后第11.0天)滞后于对照组(化疗后第6.7天)。首次化疗周期内,对照组使用升白细胞药物的患者例数(28例)显著多于试验组(11例)(P<0.05)。首次化疗后,2组患者的KPS评分均显著低于首次化疗前(P<0.05),但试验组患者KPS评分显著高于对照组(P<0.05)。首次化疗后,2组患者神疲乏力、食少纳呆、头晕心悸、恶心呕吐、自汗盗汗评分均显著高于首次化疗前,但试验组患者的自汗盗汗评分显著低于对照组(P<0.05)。2组患者首次化疗前后谷丙转氨酶、谷草转氨酶、尿素和肌酐水平均在正常范围内。结论扶正养血膏能有效降低化疗致骨髓抑制的发生率,延缓出现骨髓抑制的时间,减少临床补救性升白细胞药/升血小板药的使用量,降低中医证候评分,提高患者生活质量。
英文摘要: OBJECTIVE To observe the clinical efficacy and safety of Fuzheng yangxue ointment in the intervention of chemotherapy-induced myelosuppression . METHODS The data of 200 patients were collected retrospectively ,who were diagnosed as malignant tumors in our hospital for the first time from January 2018 to December 2020 and were to receive the chemotherapy scheme of “paclitaxel combined with platinum ”. According to whether Fuzheng yangxue ointment was used or not ,they were divided into trial group and control group ,with 100 cases in each group . The control group received routine chemotherapy ,and the trial group took Fuzheng yangxue ointment orally after the first chemotherapy until the end of this chemotherapy cycle . The time of the first occurrence of myelosuppression ,the incidence of myelosuppression ,the use of rescue drugs ,quality of life and other indicators were compared between 2 groups. RESULTS After the first chemotherapy ,white blood cell count ,neutrophil count ,the levels of platelet and hemoglobin in control group were significantly lower than those before the first chemotherapy (P<0.05). The white blood cell count and neutrophil count of patients in the trial group were significantly lower than those before the first chemotherapy(P<0.05),but significantly higher than those in the control group (P<0.05). The incidence of myelosuppression in the trial group (39.00%) was significantly lower than that (63.00%) in control group (P<0.05). The occurrence time of myelosuppression for the first time in the trial group (11.0th day after chemotherapy )was later than that in the control group (6.7th day after chemotherapy ). During the first chemotherapy cycle ,the number of patients in the control group (28 cases)using drugs for increasing white cells was significantly higher than that in the trial group (11 cases)(P<0.05). After the first chemotherapy , KPS scores of patients in both groups were significantly lower than those before the first chemotherapy (P<0.05),but KPS scores of patients in the trial group were significantly higher than those in the control group (P<0.05). After the first chemotherapy, the scores of fatigue , anorexia, dizziness,palpitation,nausea and vomiting ,and spontaneous sweating and night sweating in 2 groups were significantly higher than those before the first chemotherapy ,but the scores of spontaneous sweating and night sweating in the trial group were significantly lower than those in the control group (P<0.05). The levels of glutamic pyruvic transaminase ,glutamic oxaloacetic transaminase ,urea and creatinine in the two groups were within the normal range before and after the first chemotherapy . CONCLUSIONS Fuzheng yangxue ointment can effectively reduce the incidence of chemotherapy-induced myelosuppression ,delay the time of myelosuppression ,reduce the consumption sum of clinical remedial drug for increasing white cells/ for increasing platelet ,reduce the score of TCM syndrome and improve the quality of life of patients.
期刊: 2022年第33卷第21期
作者: 陈琳,程宗琦,姚鑫,毛叶勤
英文作者: CHEN Lin,CHENG Zongqi ,YAO Xin,MAO Yeqin
关键字: 扶正养血膏;骨髓抑制;恶性肿瘤;化疗;中医证候评分
KEYWORDS: Fuzheng yangxue ointment ;myelosuppression;malignant tumor ;chemotherapy;TCM syndrome score
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!